These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27664062)

  • 1. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes.
    Pohlmeier H; Berard L; Brulle-Wohlhueter C; Wu J; Dahmen R; Nowotny I; Klonoff D
    J Diabetes Sci Technol; 2017 Mar; 11(2):263-269. PubMed ID: 27664062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a new reusable insulin pen (ClikSTAR) in Canadian patients with type 1 and type 2 diabetes mellitus receiving insulin glargine.
    Gottesman I; Perron P; Berard L; Stewart J; Basso N; Mettimano K; Elliott T
    Diabetes Technol Ther; 2012 Oct; 14(10):926-35. PubMed ID: 22775367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes.
    Warren ML; Brod M; Håkan-Bloch J; Sparre T; Chaykin LB
    Curr Med Res Opin; 2019 Sep; 35(9):1623-1629. PubMed ID: 30974973
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.
    Yale JF; Roborel de Climens A; Aggarwal N; Dex T; Gerstein HC; Harris S; Hramiak I; Stewart J; Leiter LA
    Diabetes Ther; 2023 Feb; 14(2):377-386. PubMed ID: 36574199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
    Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
    Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a needle-free injector in Chinese patients with type 2 diabetes mellitus treated with basal insulin: a multicentre, prospective, randomised, crossover study.
    Xing Y; Xie X; Xu J; Liu J; He Q; Yang W; Zhang N; Li X; Wang L; Fu J; Zhou J; Gao B; Ming J; Liu X; Lai J; Liu T; Shi M; Ji Q
    Expert Opin Drug Deliv; 2019 Sep; 16(9):995-1002. PubMed ID: 31359813
    [No Abstract]   [Full Text] [Related]  

  • 11. A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes.
    Davies M; Bain S; Charpentier G; Flacke F; Goyeau H; Woloschak M; Hasslacher C; Vespasiani G; Edelman S
    J Diabetes Sci Technol; 2019 Sep; 13(5):881-889. PubMed ID: 30646755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of a new disposable insulin pen and injection habits of diabetes patients in everyday clinical practice].
    Böhler S; Landgraf W; Schreiber SA
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():179-87. PubMed ID: 21595146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of glucose variability in patients with type 2 diabetes administrated glargine with needle-free jet injector and conventional insulin pen.
    Sun Y; Wang J; Li H; Sun X; Su X; Ma J
    Expert Opin Drug Deliv; 2020 May; 17(5):713-717. PubMed ID: 32141347
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain.
    Riebenfeld D; Spirk D; Mathis A; Villiger L; Gerber PA; Gasser UE; Lehmann R
    Swiss Med Wkly; 2015; 145():w14114. PubMed ID: 25741640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs.
    Seufert J; Fritsche A; Pscherer S; Anderten H; Borck A; Pegelow K; Bramlage P; Pfohl M
    Diabetes Obes Metab; 2019 Feb; 21(2):439-443. PubMed ID: 30226296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the SoloSTAR insulin pen.
    Schwartz S; Vlajnic A
    Diabetes Technol Ther; 2008 Oct; 10(5):351-7. PubMed ID: 18715210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
    Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
    Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
    Ahmann A; Szeinbach SL; Gill J; Traylor L; Garg SK
    Diabetes Technol Ther; 2014 Feb; 16(2):76-83. PubMed ID: 24266497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes.
    Hancu N; Czupryniak L; Genestin E; Sourij H
    J Diabetes Sci Technol; 2011 Sep; 5(5):1224-34. PubMed ID: 22027323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
    Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
    Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.